Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Syntaxin, a discoverer and developer of a new class of biopharmaceuticals, has named Russell Greig as the new chairman of the company with immediate effect.
Subscribe to our email newsletter
Most recently, Greig has worked with GlaxoSmithKline’ (GSK) Corporate Venture Group, SR One.
Greig has held senior leadership positions in GSK, Advanced Technologies, Rib-X Pharmaceuticals and Anaphore in the past.
Syntaxin CEO Melanie Lee said that Russell’s knowledge and experience, working with both big pharma companies and in supporting high growth emerging companies will be invaluable in maximising the potential of their technology platform.